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Abstract Rhodopsin is the membrane receptor responsible for
photoreception in the vertebrate retina. Its characteristic seven-
transmembrane helical structural motif is today widely recog-
nised as a paradigm in signal transduction. Rhodopsin and the
phototransduction system are frequently used as structural and
mechanistic models for the G-protein coupled receptor super-
family. Recent advances in the activation mechanism (as derived
from the structural available data) and the implications for nor-
mal and pathological ^ in retinal disorders ^ visual function will
be reviewed.  2002 Published by Elsevier Science B.V. on
behalf of the Federation of European Biochemical Societies.
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1. Introduction
Rhodopsin has captured researchers’ attention since the iso-
lation of visual purple by Ku«hne [1], and its early proposal as
the key molecule with a central role in vision. In its pioneer
studies on the molecular basis of vision, George Wald deter-
mined the chemical nature of the chromophoric light-absorb-
ing molecule in rhodopsin. He found the antenna responsible
for capturing a photon of visible light to be the 11-cis isomer
of the derivative of vitamin A, retinal [2,3]. This system is
widespread throughout the animal kingdom and the univer-
sality of 11-cis-retinal has been clearly established as more
animal visual systems have been analysed [4]. An opsin pro-
tein and the chromophore 11-cis-retinal (or a slightly modi¢ed
derivative) are virtually found in most animals eyes, whatever
the species and evolutionary diversity. Retinal is a remarkable
molecule very well adapted for its role as the biochemical
initiator of the complex process of vision. The conservation
of this molecule provides evidence of its importance in the
physiological process in which it is involved. Nature has
found, through evolution, an extremely e¡ective molecular
design, and it is much easier for the protein part of the pig-
ment to change ‘around’ the chromophore. This allows spec-
tral ¢ne tuning of the di¡erent animal visual sensitivities to be
achieved.
Rhodopsin consists of the apoprotein opsin ^ 348 amino
acid residues ^ and the 11-cis-retinal chromophore covalently
bound to Lys-296 in the seventh transmembrane helix,
through a protonated Schi¡ base (PSB) linkage [5^8]. It be-
longs to the G-protein coupled receptor (GPCR) superfamily
[9^13]. The members of this family share a basic seven-trans-
membrane helical design (Fig. 1), and their basic function
involving binding and activating a G-protein, transducin in
the case of the visual system [14^16]. It is the main protein
component of the stacked disks found in the outer segments
of rod cells (rod outer segments, ROS) in the vertebrate ret-
ina. It was found that rhodopsin comprises about 70% of the
total protein in osmotically intact frog ROS [17], but this
percentage increases to about 90^95% after the extensive
washing steps used in the puri¢cation of ROS membranes.
ROS membranes, obtained according to a number of slightly
modi¢ed protocols from the sucrose gradient method [18], are
highly enriched in rhodopsin. Although ROS are not homo-
geneously pure samples, they have been used for many struc-
tural and functional studies with the reasonable assumption
that the obtained results were basically attributable to rho-
dopsin. Many of the studies carried out in the last decade
using wild-type and mutant recombinant rhodopsins have
dealt with puri¢ed rhodopsin. Puri¢cation of recombinant
rhodopsin is necessary to separate rhodopsin from the many
other proteins present in the mammalian cell culture systems
where recombinant opsin is usually expressed [19,20]. The
studies carried out by using ROS rhodopsin, either in mem-
branes [21^23] or in detergent-solubilised systems [24,25], in
combination with the wealth of information derived from bio-
chemical and biophysical studies on recombinant mutant rho-
dopsins [26^32], have allowed an increasing body of knowl-
edge about the structure of rhodopsin to be obtained. A
recent landmark in rhodopsin structural studies has been the
three-dimensional structural model obtained from the X-ray
crystal structure at 2.8 AF resolution [33]. This study has been
subsequently re¢ned [34] and it has stimulated a renewed in-
terest in the molecule. It has also inspired many scienti¢c
contributions, ranging from commentaries [16,35,36] to a
number of studies dealing with other members of the GPCR
superfamily [37^39]. This has strengthened the role of rhodop-
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sin as the model of this superfamily, at least for the so-called
rhodopsin-like subfamily since the possible extrapolation of
rhodopsin features to the whole superfamily may not be as
straightforward [36].
2. Rhodopsin and the mechanism of phototransduction
activation
Rhodopsin responds to the electromagnetic radiation by
means of the retinal chromophore. Upon photon capture ret-
inal isomerises through its 11^12 C^C bond to its all-trans
con¢guration. As a result of this primary photochemical
event, which is one of the fastest reactions in nature (taking
place in the order of fs), opsin evolves through a number of
thermal intermediates which cannot be detected at room tem-
perature. This leads to the formation of the active conforma-
tion metarhodopsin II (MetaII), which has retinal still cova-
lently linked to opsin. This response of the protein to the
primary physicochemical isomerisation of 11-cis-retinal in-
cludes a number of changes in the protonation state of ionis-
able residue side chains critical in the activation process. The
¢rst of these changes is deprotonation of the Schi¡ base nitro-
gen occurring as a result of the pKa change after the confor-
mational rearrangement ensuing retinal isomerisation. This is
accompanied by protonation of the Glu-113 counterion,
which has been proposed as the Schi¡ base proton acceptor
[40]. The disruption of the salt bridge between ionised Glu-113
and the PSB nitrogen, present in native dark rhodopsin, is
today clearly recognised as one of the critical switches for
the active conformation to be achieved. The presence of this
salt bridge interaction in ground state rhodopsin is clearly a
main stabilising feature of the inactive conformation of the
receptor. More recent data reveal a more complex picture
where a number of other intramolecular interactions, both
of an electrostatic but also of an steric nature, are involved
in the complete stabilisation of the inactive conformation of
the receptor. This means that several factors, other than
breakage of the Glu-113/Schi¡ base ionic interactions, are
required for the fully activated rhodopsin to be obtained
[16,41,42]. Among these the ¢rst one to be observed was
Glu-134 protonation. This step is clearly established as neces-
sary for the formation of activated rhodopsin and has been
related to the distinction of the two variants of the MetaII
conformation called MetaIIa and MetaIIb [43].
Transducin activation by MetaII initiates the visual trans-
duction pathway, which results in hyperpolarisation of the rod
cell membrane that eventually generates a nervous signal to
the brain. A number of genes encoding proteins participating
in this cascade of biochemical reactions, but also in photo-
receptor structure and others, have been associated with ret-
inal diseases, particularly retinitis pigmentosa (RP) [44]. Mu-
tations in many of these genes have been clearly determined to
be the cause of these diseases. In particular, mutations in
rhodopsin account for about 25% of all cases of the autoso-
mic form of RP and are also associated with congenital sta-
tionary night blindness (CSNB) [45].
3. Rhodopsin mutations and retinal disease
Rhodopsin was the ¢rst visual protein where a point muta-
tion was found to cause a pathological hereditary condition,
and the mutation cosegregated with the retinal disease in an
a¡ected family. This mutation in the opsin gene produced a
Pro23His substitution [46,47] in the intradiscal domain of the
protein, and was a founder mutation in the North American
population.
Fig. 1. Secondary structure model of rhodopsin based on the crystal structure data at 2.8 AF [33]. Several distinctive features are shown: (i) in
transmembrane helix III, Glu-113 (in blue), the counterion to the PSB; Cys-110, one of the two cysteine residues involved in the highly con-
served disul¢de bond with Cys-187 in the second intradiscal loop (in red circles); the ERY conserved triplet (circled in green) at the cytoplas-
mic side of the protein very important for transducin activation in the visual phototransduction cascade; (ii) in transmembrane helix VII, the
site of 11-cis-retinal attachment, Lys-296 (in yellow). Also shown are the palmitoylated Cys-322 and Cys-323 which form the putative fourth
loop by anchoring in the phospholipid membrane and providing the constraint for the eighth helix in the cytoplasmic domain, and glycosyla-
tion at Asn-2 and Asn-15.
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The study of the molecular mechanism underlying retinal
degeneration caused by mutations in retinal proteins, and
particularly in rhodopsin, is a matter of interest for the future
development of suitable therapies. The accessibility of the ret-
ina, which can be scrutinised without using invasive tech-
niques, makes it a part of the neurological system amenable
to be easily studied at the clinical level (the retina has been
called the approachable part of the brain). This interest is not
exclusive to the neuroscience ¢eld but it is also very relevant
to the elucidation of the molecular basis of disease, in partic-
ular of those diseases associated with mutations in members
of the GPCR superfamily. In this regard, correlation of the
molecular alteration in the membrane protein rhodopsin
caused by a point mutation, together with its cellular conse-
quences, with the clinical phenotype of the retinal disease in
RP patients is one of the goals that remain unattained.
Although several potential mechanisms for the degenerative
process in RP have been proposed, a clear detailed explana-
tion, other than retinal cell death may go through an apopto-
tic pathway [48,49], has not been provided yet. Several aspects
related to retinal diseases caused by mutations in rhodopsin
are still a puzzle to scientists involved in vision research;
among them: (i) rhodopsin mutations occurring in rod cells
result also in cone cell death; (ii) very similar mutations in
rhodopsin can cause di¡erent clinical phenotypes like those
associated with RP and CSNB; (iii) the same mutation has
very di¡erent consequences, in individuals of the same family,
on the onset and severity of the RP condition. While the ¢rst
question remains unanswered, the third question seems to
obviously point to the involvement of other factors, other
than the mutation, in the physiopathology of RP. Concerning
the di¡erence between RP and CSNB there is increasing evi-
dence that these two conditions may have di¡erent molecular
mechanisms as will be discussed below.
Recent studies suggest interesting novel molecular mecha-
nisms for RP, like the one recently proposed where rod cell
death could result from activation of mislocalised opsin [50].
Another proposal has been made suggesting that spreading of
Fig. 2. Schematic representation of the main consequence of mutations associated with RP in rhodopsin at the structural level. The folded con-
formation in the dark has the right con¢guration of the retinal binding pocket and it allows e⁄cient ¢nding of this ligand by maintaining the
correct set of interactions. The RP mutation results in an altered conformation of the protein which would disrupt the compact tertiary struc-
ture in the intradiscal domain. This would, in turn, allow the formation of a wrong disul¢de bond between Cys-185 and Cys-187 that would ir-
reversibly lock the protein in its misfolded conformation. One of the consequences would be that the correct binding pocket of the retinal is
not formed and 11-cis-retinal binding is, therefore, either abolished or severely impaired. Other structural e¡ects of this misfolding may be
changes in the helices and in the cytoplasmic loops and C-terminal tail as well.
Fig. 3. A: Amino acid side chain arrangement of the residues mutated in CSNB, namely Gly-90, Ala-292 and Thr-94, in the vicinity of the
PSB and close to the Glu-113 counterion. B: Location of the water molecule proposed to be in this region [65] in proximity to Glu-113 and
Thr-94. Disruption of the network of electrostatic interactions a¡ecting these residues could allow a change in the pKa of the PSB. This would
be in the basis of the molecular mechanism underlying CSNB (see text).
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photoreceptor cell death from rods to cones may be caused by
gap junctions that exist between these photoreceptor subtypes
[51].
4. Mutations in rhodopsin associated with RP
Up to 150 mutations have been reported to date in the
opsin gene associated with the retinal degenerative RP since
the Pro23His mutation, in the intradiscal domain of the pro-
tein, was ¢rst reported in 1990 [44]. Most of them are related
with the autosomical form of the disease (adRP) and are
single point missense mutations. These mutations are found
widespread throughout the opsin gene and they are distrib-
uted along the three domains of the protein, the intradiscal,
transmembrane and cytoplasmic domains. This plethora of
mutations can be regarded as ‘natural hints’ of residues in
the polypeptide opsin chain important for its optimal struc-
ture and/or function. The large number of mutations found
and their di¡erent location may be indicative of a highly so-
phisticated arrangement of physicochemical interactions in the
three-dimensional structure of the native rhodopsin molecule.
This has been naturally designed to account for an optimised
protein system that can control several very important phys-
iological aspects of the complex phenomenon of vision.
Among these, we can highlight the precise set of amino acid
side chain interactions with the retinal chromophore in the
retinal binding pocket to allow ¢ne tuning of the di¡erent
visual pigments. Also, the dark conformation of the receptor
has an extraordinary stability, with dark noise resulting from
thermal activation of the receptor being very low to allow
adaptation to very low light intensity levels to be achieved.
At the same time the system is also extremely e⁄cient in the
activation of the phototransduction cascade and in the ampli-
¢cation of the system. The activation and inactivation pro-
cesses in which rhodopsin is involved, in the visual biochem-
ical cycle, are precisely modulated by a number of very well
organised sets of protein^protein interactions where metal
ions play also an important role. The details of these inter-
actions are currently being unravelled and there is a growing
body of evidence that supports the view of a complex but very
well designed biochemical system. With this outlined picture it
is easily understood that rhodopsin mutations responsible for
RP must be altering this precise network of interactions as a
consequence of the di¡erent degrees of perturbation of the
rhodopsin structure. Obviously, modi¢cations in the native
conformation of rhodopsin as a result of RP mutation can
result in altered function, i.e. alterations in transducin activa-
tion. In the past decade several research groups have devoted
sustained e¡ort to elucidate the molecular mechanism(s)
underlying the retinal RP pathology. The ultimate goal of
this research is to contribute to the development of therapeu-
tic solutions to the disease. Several mechanisms have been
outlined but there is no clear explanation about the molecular
link between the rhodopsin mutation and the rod cell degen-
erative process. From a biochemical standpoint it is undoubt-
edly of interest to obtain detailed knowledge of the phenotype
of the mutant proteins and to correlate the molecular defect
observed with the clinical phenotype of the a¡ected RP pa-
tients. This clinical correlation with the laboratory results has
turned out to be not straightforward due to the extreme clin-
ical and genetic heterogeneity of the disease. The onset and
the progression of the disease have been found to be very
di¡erent in relatives carrying the same opsin mutation. Be-
sides, there are some RP mutations that apparently do not
alter signi¢cantly the structure or function of the protein, so it
is not clear which might be the cause of the disease in these
cases. In spite of these problems, it is interesting to try to
establish a correlation between protein structural features
and RP patient clinical phenotype taking into account the
di¡erent current hypothesis of how these two aspects may
be linked.
Protein misfolding has been proposed to be one of the main
biochemical causes of RP in the case of rhodopsin mutations
[52^54], and molecular chaperones have been also involved in
RP [55]. At the molecular level non-native disul¢de bond for-
mation between Cys-185 and Cys-187 has been recently shown
in misfolded opsin (non-retinal binding) fractions by mass
spectrometry [56] (Fig. 2). Misfolding seems to be a general
theme in many of the diseases caused by mutations, and par-
ticularly with those associated with rhodopsin in RP. Altered
stability and/or function may also have relevance for a num-
ber of given mutations. In this regard, abnormal functioning
resulting in reduced activity or hyperactivity could also play a
role in RP by altering the stoichiometric balance of the di¡er-
ent proteins involved in the phototransduction biochemical
reactions. It is important to note that hyperactivity, in the
case of RP, is not necessarily related to constitutive activity
(that is activity in the absence of ligand or light), but to in-
creased initial activation rate in some mutants (A. Andres, E.
Roca, P. Garriga and J. Manyosa, to be submitted). Some
mutations, like those in the C-terminal tail, might a¡ect
post-Golgi tra⁄cking of rhodopsin and may result in mislo-
calised rhodopsin [57]. In this case the aforementioned mech-
anism of rod cell death triggered by mislocalised opsin [50]
would provide an explanation for the biochemical basis of
RP related to this kind of mutations. This may be the case
for several mutations, like Gln344ter and Pro347Leu, known
to have a clinical severe phenotype, located in the C-terminal
sequence QVS(A)PA which has been proposed to comprise a
signal recognisable by factors in the trans-Golgi network [58].
5. Mutations in rhodopsin associated with CSNB
CSNB is another retinal disease also associated with rho-
dopsin mutations. In contrast with RP, only three mutations
have been found associated with CSNB in rhodopsin. It is
possible that the more benign phenotype of this pathology
has prevented more mutations to be discovered. Two of these
mutations are found in the second transmembrane helix of
rhodopsin at Gly-90 and Thr-94. These correspond to
Gly90Asp [59] and Thr94Ile, which has been the latest one
to be reported [60]. The other mutation, Ala292Glu [61] is
located in the seventh transmembrane helix, in proximity to
the site of retinal attachment at Lys-296. The three residues
are located in the environment of the PSB and the Glu-113
counterion (Fig. 3). The electrostatic interaction between the
Glu-113 counterion and the PSB nitrogen is known to be one
of the key features in maintaining the inactive conformation
of the receptor. Relieving this constraint by breakage of the
salt bridge has been proposed to be one of the requirements
for the active conformation to be achieved [62]. In the case of
the Gly90Asp mutation a molecular mechanism was proposed
for CSNB on the basis of constitutive activation of the mutant
receptor [59]. This mutation has been analysed in some detail
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[63] and the mechanism of constitutive light adaptation, with-
out rod cell loss, has been recently con¢rmed in transgenic
mice carrying the Gly90Asp mutation [64]. The same mecha-
nism was also proposed for the Ala292Glu mutation [62]. In
the two cases, the proposed mechanism involves partial dis-
ruption of the native salt bridge, by electrostatic competition
of the introduced residue side chain with Glu-113 for the PSB
nitrogen. According to this molecular model the resulting con-
stitutive activity in the dark, induced by the structural changes
caused by the mutation, would be in the basis of the physio-
logical e¡ects seen in CSNB. In addition to its importance as
a visual pathology, the study of CSNB is interesting because it
can be a model of the ¢rst stages of RP. The molecular mech-
anism of the novel mutation found in transmembrane helix II,
Thr94Ile, does not appear to ¢t in the ‘electrostatic model’
outlined above. In this particular case, the hydrophobic and
bulkier isoleucine side chain replaces the polar hydrophilic
threonine side chain, and there is no possibility of electrostatic
competition as proposed for the other two CSNB related mu-
tants. The The94Ile mutant shows highly di¡erentiated fea-
tures when compared to other mutants, namely very high
thermal instability, high hydroxylamine reactivity and an ex-
tremely long-lived MetaII species (E. Ramon, L. del Valle and
P. Garriga, to be submitted). Constitutive activity of this mu-
tant, although presumed, has not been established yet and it
may be di⁄cult to determine possibly because of stability
problems of the protein. Thr-94 is located in helix II one helix
turn apart of Gly-90 and seen to be in close proximity to Glu-
113 in the three-dimensional model of rhodopsin derived from
the crystal structure at 2.8 AF resolution [33]. Recently the
location of water molecules and its role in the activation
mechanism of rhodopsin has been reported [65]. One of the
water molecules would be located in proximity to the 90^94
region because it has been proposed to be in the vicinity of
Phe-91 [65]. It is possible that Thr-94 is interacting with Glu-
113 directly or through a water molecule. Replacement by
isoleucine would eliminate this interaction, and this could re-
sult in a lowering of the pKa of the PSB with a similar out-
come to that caused by the other two mutations. Thus, the
emerging picture is more complex than previously thought
and may involve multi-part interactions in the vicinity of
the PSB. With this vision in mind, the three CSNB mutations
would be acting by means of a mechanism involving changes
in electrostatic interactions and subsequent lowering of the
pKa for the PSB, thus facilitating its deprotonation.
Taking into account all the information known to date, it is
likely that the molecular defect in rhodopsin underlying RP is
related to partial or complete misfolding and the resulting
inability of the mutant proteins to bind 11-cis-retinal. In con-
trast, mutations associated with CSNB a¡ect amino acid res-
idues that cluster around the PSB linkage and are presumably
associated with changes in conformational stability and the
protonated status of the PSB nitrogen. In this latter case,
the derived functional alterations of the mutant receptors
would be in the basis of the observed phenotypes in CSNB,
rather than gross structural misfolding as associated with RP
mutations.
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